Clearstead Advisors’s Alzamend Neuro ALZN Stock Holding History

Clearstead Advisors’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$10.6K	–	3663
2026 Q1	$10.6K	Hold	10,000	–	–	﹤0.01%	1573
2025 Q4	$18.2K	Hold	10,000	–	–	﹤0.01%	1744
2025 Q3	$23.8K	Buy	+10,000	New	+$26K	﹤0.01%	1566

Other funds holding ALZN

KWM

KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Clearstead Advisors's ALZN Position: Q2 2026 in Review

Clearstead Advisors sold out of Alzamend Neuro (ALZN) in Q2 2026, closing a stake of 10,000 shares — an estimated $10.6K sold.

Clearstead Advisors first reported a position in ALZN in Q3 2025 and held it in 3 quarters. The position peaked at $23.8K in Q3 2025. 5 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

Clearstead Advisors reported no remaining Alzamend Neuro position as of Q2 2026 after selling out during the quarter.
Clearstead Advisors sold 10,000 Alzamend Neuro shares in Q2 2026, an estimated $10.6K.
Clearstead Advisors first reported a position in Alzamend Neuro in Q3 2025 and held it in 3 quarters.
Clearstead Advisors's Alzamend Neuro position peaked at $23.8K in Q3 2025.
5 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.